METAVIA INC (MTVA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.75-4.89%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · MTVA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue clinical trials and data readouts for DA-1726, focusing on higher dose titration studies and liver-related outcomes in obesity and MASH.
Stated as a priority in 3 quarters including 2026-Q1 and 2026-Q2 and a recent undated release. Management highlights successful dosing of all active patients at highest planned doses in Phase 1 Part 3 and expects topline data in Q4 2026. DA-1726 demonstrated up to 9.1% mean weight loss at Day 54 with liver-related improvements. The trajectory is delivering on clinical development milestones with progressive data readouts.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“All active patients successfully reached highest planned dose levels of 48 mg and 64 mg in ongoing Phase 1 Part 3 study of DA-1726.”
“Dosed first patient in Part 3 of Phase 1 trial evaluating DA-1726 with one-step titration to 48 mg and two-step to 64 mg.”
Advance vanoglipel development as a combination therapy backbone for metabolic and liver diseases including MASH and type 2 diabetes.
Stated in 3 quarters including 2026-Q1 and 2026-Q2 and an undated release. Management presented preclinical data showing synergistic effects of vanoglipel combined with resmetirom in MASH and metformin in type 2 diabetes, supporting its role as a combination therapy backbone. The priority is consistently emphasized with supportive preclinical evidence, indicating ongoing development focus.
“Presented preclinical combination data at ADA 2026 showing synergistic effects of vanoglipel with resmetirom and metformin.”
“Announced positive AI-modeling results supporting vanoglipel's target engagement in MASH and type 2 diabetes.”
Ensure adequate cash and capital resources to fund operations through the end of 2026.
Stated as a priority in 3 quarters including 2025-Q4, 2026-Q1, and 2026-Q2. Cash and cash equivalents increased from $10.3 million at 2025-Q4 to $12.6 million at 2026-Q2. Management expects this cash position, supported by proceeds from a January 2026 public offering, will fund operations through 2026. The trajectory shows maintenance of sufficient liquidity as committed.
“Cash and cash equivalents was $12.6 million as of June 30, 2026; company expects cash position adequate to fund operations through 2026.”
“Cash and cash equivalents was $13.7 million as of March 31, 2026; company expects cash position adequate to fund operations into Q4 2026.”
“$10.3 million in cash and cash equivalents at end of 2025 and proceeds from January 2026 public offering expected to fund company into Q4 2026.”
Focus on managing operating expenses to reduce losses and move toward improved profitability.
Stated as a priority in 2 quarters, 2026-Q1 and 2026-Q2. Operating expenses increased from $4.3 million in 2025-Q2 to $5.4 million in 2026-Q2, driven by higher R&D costs. Net loss rose from $4.0 million to $5.3 million over the same period. Despite management's focus, operating losses have increased, indicating limited progress toward improved profitability.
“Total operating expenses were $5.4 million in Q2 2026, up from $4.3 million in Q2 2025; net loss was $5.3 million versus $4.0 million prior year.”
“Operating expenses were $4.0 million in Q1 2026, slightly higher than $3.9 million in Q1 2025; net loss was $3.8 million versus $3.7 million prior year.”
Address ongoing negative cash flow from operations to improve financial sustainability.
Stated as a priority in 2 quarters, 2025-Q4 and 2026-Q1. Operating cash flow remained negative at -$4.9 million in 2025-Q4 and -$4.3 million in 2026-Q1, indicating ongoing cash burn. The slight improvement in cash flow is limited, showing persistent negative operating cash flow and ongoing financial management challenges.
“Cash from operating activities was negative $4.3 million in Q1 2026.”
“Cash from operating activities was negative $4.9 million in Q4 2025.”
Over the trailing year it converted 0.97x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
10 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.